Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-103 in Parkinson's Disease
NCT00086294Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pimavanserin in Parkinson's disease (PD) and dyskinesia (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Started Jun 2004; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)dyskinesia
Beyond the preview
Go deeper on NCT00086294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086294.